Capital Fund Management (CFM)
TEVA icon

Capital Fund Management (CFM)’s Teva Pharmaceuticals TEVA Stock Holding History

Capital Fund Management (CFM)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-114,656
Closed -$2.01M – 2681
2025
Q2 		$1.92M Buy
+114,656
New +$1.85M 0.01% 1704
2025
Q1 		– Sell
-199,031
Closed -$3.56M – 2344
2024
Q4 		$4.39M Buy
+199,031
New +$3.62M 0.01% 1141
2024
Q3 		– Sell
-40,745
Closed -$713K – 2154
2024
Q2 		$662K Sell
40,745
-147,169
-78% -$2.27M ﹤0.01% 1701
2024
Q1 		$2.65M Sell
187,914
-312,633
-62% -$3.94M 0.01% 1319
2023
Q4 		$5.23M Buy
500,547
+62,903
+14% +$587K 0.01% 1067
2023
Q3 		$4.46M Sell
437,644
-924,149
-68% -$8.61M 0.02% 998
2023
Q2 		$10.3M Buy
1,361,793
+707,901
+108% +$5.74M 0.04% 549
2023
Q1 		$5.79M Sell
653,892
-165,467
-20% -$1.64M 0.03% 687
2022
Q4 		$7.47M Sell
819,359
-118,373
-13% -$1.03M 0.05% 499
2022
Q3 		$7.57M Sell
937,732
-246,878
-21% -$2.18M 0.06% 413
2022
Q2 		$8.91M Buy
1,184,610
+780,973
+193% +$6.8M 0.08% 343
2022
Q1 		$3.79M Buy
+403,637
New +$3.37M 0.03% 685
2017
Q2 		– Sell
-76,476
Closed -$2.37M – 1724
2017
Q1 		$2.45M Sell
76,476
-65,768
-46% -$2.24M 0.02% 677
2016
Q4 		$5.16M Sell
142,244
-994,349
-87% -$39.7M 0.04% 487
2016
Q3 		$52.3M Buy
1,136,593
+398,528
+54% +$20.8M 0.48% 41
2016
Q2 		$37.1M Buy
738,065
+432,272
+141% +$23M 0.35% 70
2016
Q1 		$16.4M Sell
305,793
-75,500
-20% -$4.43M 0.16% 168
2015
Q4 		$25M Buy
381,293
+281,269
+281% +$17.4M 0.26% 96
2015
Q3 		$5.65M Sell
100,024
-638,523
-86% -$41.4M 0.06% 366
2015
Q2 		$43.6M Buy
738,547
+506,525
+218% +$31.2M 0.55% 26
2015
Q1 		$14.5M Sell
232,022
-62,295
-21% -$3.62M 0.2% 138
2014
Q4 		$16.9M Buy
+294,317
New +$16.4M 0.2% 123
2014
Q1 		– Sell
-46,175
Closed -$2.13M – 1955
2013
Q4 		$1.85M Sell
46,175
-88,867
-66% -$3.5M 0.02% 730
2013
Q3 		$5.1M Sell
135,042
-224,635
-62% -$8.76M 0.07% 351
2013
Q2 		$14.1M Buy
+359,677
New +$14M 0.22% 88

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Fund Management (CFM)'s TEVA Position: Q3 2025 in Review

Capital Fund Management (CFM) sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 114,656 shares — an estimated $2.01M sold.

Capital Fund Management (CFM) first reported a position in TEVA in Q2 2013 and held it in 25 quarters. The position peaked at $52.3M in Q3 2016. 550 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Capital Fund Management (CFM) reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 114,656 Teva Pharmaceuticals shares in Q3 2025, an estimated $2.01M.
  • Capital Fund Management (CFM) first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 25 quarters.
  • Capital Fund Management (CFM)'s Teva Pharmaceuticals position peaked at $52.3M in Q3 2016.
  • 550 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2025, filed 13 Nov 2025.